Search alternatives:
significant decrease » significant increase (Expand Search), significantly increased (Expand Search)
decrease risks » increased risks (Expand Search), disease risks (Expand Search), decrease rice (Expand Search)
teer decrease » greater decrease (Expand Search)
mean decrease » a decrease (Expand Search)
Showing 61 - 80 results of 22,987 for search '(( significant decrease risks ) OR ( significantly ((teer decrease) OR (mean decrease)) ))', query time: 0.39s Refine Results
  1. 61
    Mean and standard deviation of the three dimensions and of the global score of STS before COVID-19.

    Mean and standard deviation of the three dimensions and of the global score of STS before COVID-19. by Martina Gnerre (12329356)

    Published 2022
    Subjects:
    Save to List
    Saved in:
  2. 62
    Mean and standard deviation of the three dimensions and of the global score of STS during COVID-19.

    Mean and standard deviation of the three dimensions and of the global score of STS during COVID-19. by Martina Gnerre (12329356)

    Published 2022
    Subjects:
    Save to List
    Saved in:
  3. 63
    Mean and standard deviation of the three dimensions and of the global score of STS after COVID-19.

    Mean and standard deviation of the three dimensions and of the global score of STS after COVID-19. by Martina Gnerre (12329356)

    Published 2022
    Subjects:
    Save to List
    Saved in:
  4. 64
    Bias risk assessments for each RCT study.

    Bias risk assessments for each RCT study. by Xin Liu (43569)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  5. 65
    Bias risk assessments for each RCS study.

    Bias risk assessments for each RCS study. by Xin Liu (43569)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  6. 66
    Forest plots illustrate the mean difference in creatinine level with subgroup analysis based on patients’ age.

    Forest plots illustrate the mean difference in creatinine level with subgroup analysis based on patients’ age. by Mohamed R. Abdelraouf (21501468)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  7. 67
    The difference in mean score for the five scales of the RISE-Q for breakfast and main meal among study participants (n = 835).

    The difference in mean score for the five scales of the RISE-Q for breakfast and main meal among study participants (n = 835). by Leila Cheikh Ismail (3152526)

    Published 2023
    Subjects:
    Save to List
    Saved in:
  8. 68
    SLE decreases risk for hormonal cancers.

    SLE decreases risk for hormonal cancers. by Deborah K. Johnson (10001156)

    Published 2021
    “…(a) Breast cancer incidence in female SLE cohort is significantly decreased by SLE status (OR 0.52, 95% CI 0.35, 0.74, p = 0.0036). …”
    Save to List
    Saved in:
  9. 69
    Mean scores compared with paired-samples <i>t</i>-test (and related effect sizes) at pre- and post-test (<i>n</i> = 900).

    Mean scores compared with paired-samples <i>t</i>-test (and related effect sizes) at pre- and post-test (<i>n</i> = 900). by Maria Anna Donati (6735548)

    Published 2022
    Subjects:
    Save to List
    Saved in:
  10. 70
    Mean scores compared with paired-samples <i>t</i>-test (and related effect sizes) at pre- and follow-up (<i>n</i> = 662).

    Mean scores compared with paired-samples <i>t</i>-test (and related effect sizes) at pre- and follow-up (<i>n</i> = 662). by Maria Anna Donati (6735548)

    Published 2022
    Subjects:
    Save to List
    Saved in:
  11. 71
    Summary of post-treatment disease course measures from MDMA-AT publications.

    Summary of post-treatment disease course measures from MDMA-AT publications. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  12. 72
    Study selection criteria.

    Study selection criteria. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  13. 73
    Summary of post-treatment CAPS score changes from clinical trials with FDA-approved medications.

    Summary of post-treatment CAPS score changes from clinical trials with FDA-approved medications. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  14. 74
    Disease course measures after the PTSD treatments.

    Disease course measures after the PTSD treatments. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  15. 75
    PICOS criteria for the SLR.

    PICOS criteria for the SLR. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  16. 76
    Summary of post-treatment CAPS score changes from MDMA-AT publications.

    Summary of post-treatment CAPS score changes from MDMA-AT publications. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  17. 77
    Summary of post-treatment disease course measures from off-label medications clinical trials.

    Summary of post-treatment disease course measures from off-label medications clinical trials. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  18. 78
    Summary of post-treatment CAPS score changes from clinical trials with psychotherapies.

    Summary of post-treatment CAPS score changes from clinical trials with psychotherapies. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  19. 79
    Summary of clinical studies of FDA-approved medications for PTSD: Disease course outcomes.

    Summary of clinical studies of FDA-approved medications for PTSD: Disease course outcomes. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  20. 80
    Summary of post-treatment disease course measures from clinical trials with psychotherapies.

    Summary of post-treatment disease course measures from clinical trials with psychotherapies. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:

Search Tools: